06.05.04 16:17 Ancienneté: 6 yrs
Ipsogen announces selection by the French network of anti-cancer centres to investigate gene expression in breast tumours treated with anthracycline therapy.
Categorie: Cancer du sein
“This agreement with FNCLCC is an important critical step in applying genomic tools to improve standard chemotherapy regimen in breast cancer. This large scale genomic study will provide homogeneous treatments and monitoring conditions which are usually difficult to achieve in retrospective studies. This pioneering study - the first of its kind in the world to our knowledge - will contribute to the validation of biomarkers currently identified by IPSOGEN and its current academic partners” said Vincent Fert, President and CEO of IPSOGEN.
Read more
IPSOGEN today announced that it has been selected under a call for proposal, by the French network of anti-cancer centers (FNCLCC) to investigate genes expression of breast cancer tumours treated with anthracycline chemotherapy. The study will involve about 150 samples collected in the framework of a randomized phase III study promoted by FNCLCC involving 84 French and Belgian hospitals.
